Drugs · acquisition-cost intelligence
tacrolimus
· ingredient tacrolimusCalcineurin inhibitors· TACROLIMUS 1 mg/g; TACROLIMUS .3 mg/g
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per GM
$0.89046
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per GM — the trend nobody else shows. 6 weeks.
2025-12-172026-05-20
Same-ingredient options by acquisition cost
Other tacrolimus products, cheapest acquisition cost first. Per GM — confirm strength/form equivalence before switching.
| Product | NADAC / GM | vs this |
|---|---|---|
| tacrolimus | $0.16131 | −$0.72910 |
| Tacrolimus | $0.16131 | −$0.72910 |
| Tacrolimus | $0.41056 | −$0.47990 |
| Tacrolimus | $0.89863 | +$0.00820 |
| Prograf | $6.19 | +$5.30 |
Medicare Part D coverage · CY2026
On 328 plan formularies · typical tier 4
Prior auth 41% · Step therapy 6% · Quantity limit 68% of formularies
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.